Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  New England Journal of Medicine

• Publication date

  1998-02-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM199802263380902PMID 9475763
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic myeloid leukemia

  1997cited by this paper
• Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro.

  1997cited by this paper
• Activation of phosphatidylinositol 3'-kinase by insulin-like growth factor-I rescues promyeloid cells from apoptosis and permits their differentiation into granulocytes.

  1997cited by this paper
• The expression of Bcl-x is downregulated during differentiation of human hematopoietic progenitor cells along the granulocyte but not the monocyte/macrophage lineage.

  1997cited by this paper
• Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL.

  1996cited by this paper
• Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2.

  1996cited by this paper
• Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells.

  1995cited by this paper
• Hematology: Basic Principles and Practice, 2nd ed

  1995cited by this paper
• Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium.

  1994cited by this paper
• Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera

  1994cited by this paper
• Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera.

  1994cited by this paper
• Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium [see comments]

  1994cited by this paper
• Primary familial and congenital polycythaemia

  1993cited by this paper
• bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

  1993cited by this paper
• Primary familial and congenital polycythaemia.

  1993cited by this paper
• Apoptosis of human erythroid colony‐forming cells is decreased by stem cell factor and insulin‐like growth factor I as well as erythropoietin

  1993cited by this paper
• Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production.

  1993cited by this paper
• Mechanism of action of hydroxyurea.

  1992cited by this paper
• Erythropoietin.

  1991cited by this paper
• Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells.

  1990cited by this paper
• Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells

  1988cited by this paper
• A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia

  1986cited by this paper
• A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia.

  1986cited by this paper
• Determination of serum immunoreactive erythropoietin in the investigation of erythrocytosis.

  1986cited by this paper
• Erythroid colony formation in primary thrombocythaemia: evidence of hypersensitivity to erythropoietin

  1984cited by this paper
• Erythropoietin radioimmunoassay in evaluating patients with polycythemia.

  1981cited by this paper
• Erythropoiesis in familial erythrocytosis.

  1977cited by this paper
• Diagnosis and classification of the polycythemias.

  1975cited by this paper
• Erythropietic colonies in cultures of human marrow.

  1974cited by this paper
• Letter: Bone-marrow responses in polycythemia vera.

  1974cited by this paper
• Letter: Bone-marrow responses in polycythemia vera.

  1974cited by this paper

• The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies

  2025cites this paper
• Innovative strategies for mitochondrial dysfunction in myeloproliferative neoplasms a step toward precision medicine

  2025cites this paper
• Bcl-x short-isoform is essential for maintaining homeostasis of multiple tissues.

  2023cites this paper
• Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms

  2023cites this paper
• von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well‐controlled platelet counts

  2022cites this paper
• Advances in understanding the molecular basis of clonal hematopoiesis.

  2022cites this paper
• Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations

  2022cites this paper
• Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.

  2022cites this paper
• Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

  2022cites this paper
• The JAK2 mutation.

  2021cites this paper
• Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera

  2021cites this paper
• Suppression of multiple anti‐apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms

  2021cites this paper
• BH3 profiling allows to functionally characterize T-cell prolymphocytic leukemia and to identify innovative therapeutic options

  2021cites this paper
• Alternative splicing of BCL-X and implications for treating hematological malignancies

  2021cites this paper
• Eryptosis in polycythemia vera and essential thrombocythemia* Eryptoza w czerwienicy prawdziwej i nadpłytkowości samoistnej

  2020influential citation
• Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms

  2020cites this paper
• BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells

  2020cites this paper
• Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond

  2020cites this paper
• Myeloproliferative and lymphoproliferative disorders: State of the art

  2019cites this paper
• The rise of apoptosis: targeting apoptosis in hematologic malignancies.

  2018cites this paper
• LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone

  2018cites this paper
• Apoptotic Endonuclease EndoG Induces Alternative Splicing of Telomerase TERT Catalytic Subunit, Caspase-2, DNase I, and BCL-x in Human, Murine, and Rat CD4+ T Lymphocytes

  2018cites this paper
• The effect of exogenous in vitro expression of wild type and mutant JAK2 in erythroblast progenitors

  2017cites this paper
• Myeloproliferative Neoplasms

  2017cites this paper
• An integrated method for the identification of novel genes related to oral cancer

  2017cites this paper
• After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.

  2017cites this paper
• DC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis

  2017cites this paper
• 12 Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia

  2017cites this paper
• Novel Therapies for Myelofibrosis

  2017cites this paper
• Université de Montréal-Thèse numérique

  2016cites this paper
• Immunotherapy and polycythemia vera

  2016cites this paper
• Ruxolitinib: a targeted treatment option for patients with polycythemia vera

  2016cites this paper
• Bcl‐2 proteins in development, health, and disease of the hematopoietic system

  2016cites this paper
• Treatment of Myelofibrosis: A Moving Target

  2016cites this paper
• Ruxolitinib: a targeted treatment option for patients with polycythemia vera Blood and Lymphatic Cancer: Targets and Therapy

  2016cites this paper
• Efeito de SMADs e de microRNAs na expressão gênica de TGF-β1 e seu papel na angiogênese em pacientes com mielofibrose e trombocitemia essencial

  2015cites this paper
• Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

  2015cites this paper
• The future of JAK inhibition in myelofibrosis and beyond.

  2014cites this paper
• BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

  2014cites this paper
• and determinants of response in myeloid malignancies

  2014cites this paper
• Erythropoiesis: from molecular pathways to system properties.

  2014cites this paper
• the V617F JAK-2 mutation Ph-negative chronic myeloproliferative diseases and is independent of Different STAT-3 and STAT-5 phosphorylation discriminates among

  2013cites this paper
• Molecular Pathways Molecular Pathways : JAK / STAT Pathway : Mutations , Inhibitors , and Resistance

  2013cites this paper
• Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

  2013cites this paper
• The Pathogenesis, Diagnosis, and Treatment of Polycythaemia Vera

  2013cites this paper
• families with myeloproliferative disorders Genetic and clinical implications of the Val617Phe JAK2 mutation in 72

  2013cites this paper
• JAK2V617F-positive Myeloproliferative Neoplasms : KI mouse models, Interferon-α therapy and clonal architecture

  2013cites this paper
• Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

  2013cites this paper
• Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms

  2012cites this paper
• A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2

  2012cites this paper
• polycythemia vera erythroid precursor cells expression in short Increased death receptor resistance and FLIP

  2012cites this paper
• New pieces of a puzzle: the current biological picture of MPN.

  2012cites this paper
• MOLEKULARNI MEHANIZMI PATOGENEZE MIJELOPROLIFERATIVNIH NEOPLAZIJA: POREMEĆAJ EKSPRESIJE GENA UKLJUČENIH U PROLIFERACIJU I APOPTOZU

  2012cites this paper
• Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy

  2012cites this paper
• İSTANBUL BİLİM ÜNİVERSİTESİ TIP FAKÜLTESİ İÇ HASTALIKLARI ANABİLİM DALI ESANSİYEL TROMBOSİTEMİ VE PRİMER MİYELOFİBROZ OLGULARINDA TET2 MUTASYONU

  2012cites this paper
• Contrasting dynamic responses in vivo of the Bcl-xL and Bim erythropoietic survival pathways.

  2012cites this paper
• Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis

  2012cites this paper
• Chronic Myeloproliferative Disorders:From Molecular Pathogenesis to Targeted Therapy

  2012cites this paper
• The Evaluation of Polycythemia and the Diagnosis of Polycythemia Vera

  2012cites this paper
• PV, ET, PMFの分子病態と治療概論

  2012cites this paper
• Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia

  2012cites this paper
• Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.

  2012cites this paper
• JAK2 inhibitors in the treatment of myeloproliferative neoplasms

  2012cites this paper
• The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

  2012cites this paper
• The cell cycle regulator CDC 25 A is a target for JAK 2 V 617 F oncogene

  2012cites this paper
• Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival

  2011influential citation
• New JAK2 inhibitors for myeloproliferative neoplasms

  2011cites this paper
• Acquired Mutation of the Tyrosine Kinase JAK2V617F in Egyptian Patients with Myeloid Disorders

  2011influential citation
• Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor

  2011cites this paper
• Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

  2011cites this paper
• Dynamics of Erythropoietic Survival Pathways In Vivo: A Dissertation

  2011cites this paper
• Introduction to “Classic” Chronic Myeloproliferative Disorders (CMPDs) — Molecular and Cellular Biology

  2010cites this paper
• Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

  2010cites this paper
• A CK2-DE PENDENT MECHANISM FOR ACTIVATION OF THE JAK-STAT SIGNALING PATHWAY: IMPLICATIONS FOR CANCER BIOLOGY

  2010cites this paper
• JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms

  2010cites this paper
• Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.

  2010cites this paper
• PREFERENTIAL NUCLEAR ACCUMULATION OF JAK 2 V 617 F IN CD 34 + BUT NOT IN GRANULOCYTIC , MEGAKARYOCYTIC OR ERYTHROID CELLS OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA

  2010cites this paper
• Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells

  2010cites this paper
• Myeloproliferative neoplasms: new translational therapies.

  2010cites this paper
• The role of FasR/FasL system in pathogenesis of myeloprolyferative neoplasms

  2010cites this paper
• The molecular pathogenesis of myeloproliferative neoplasms

  2010cites this paper
• Hsp70 est un nouveau régulateur majeur de l'érythropoïèse empêchant le clivage du facteur de transcription GATA-1 par la caspase-3 au cours de la différenciation.

  2010cites this paper
• Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells.

  2010cites this paper
• Brief report Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon (cid:1) specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells

  2010cites this paper
• Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells

  2010cites this paper
• An inhibitor of Janus kinase 2 prevents polycythemia in mice.

  2009cites this paper
• The complete evaluation of erythrocytosis: congenital and acquired

  2009cites this paper
• Imbalance of DNA‐dependent protein kinase subunits in polycythemia vera peripheral blood stem cells

  2009cites this paper
• Thrombopoietin in normal and neoplastic stem cell development.

  2009cites this paper
• Phospho‐STAT5 and phospho‐Akt expression in chronic myeloproliferative neoplasms

  2009cites this paper
• Hemopoiesis in Ph-negative chronic myeloproliferative disorders.

  2009cites this paper
• Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage

  2009cites this paper
• PAPEL DE LA ACTIVACIÓN PLAQUETARIA Y LEUCOCITARIA EN LA PATOGENIA DE LA TROMBOSIS EN LA TROMBOCITEMIA ESENCIAL

  2009cites this paper
• The Role of Janus Kinase 2 (JAK2) in the Pathologenesis of Myeloproliferative Disorders@@@دور التايروسين كاينيز في تطور سرطان الدم المزمن

  2009cites this paper
• Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.

  2009cites this paper
• Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

  2008cites this paper
• Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.

  2008cites this paper
• Genexpressionsanalysen von CD34+ hämatopoietischen Stamm- und Progenitorzellen bei Patienten mit Polycythaemia vera

  2008cites this paper
• JAK 2 V 617 F mutation and the myeloproliferative disorders

  2008cites this paper
• CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice.

  2008cites this paper